Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **antigen presentation pathway via antigen-presenting cell (APC)** refers to the multi-step immunological process by which specialized cells known as antigen-presenting cells (mainly dendritic cells, macrophages, and B cells) process protein antigens and display the resulting peptide fragments on their cell surface bound to major histocompatibility complex (MHC) molecules[1][2][3][4]. This surface presentation allows T cells to recognize these peptides through their T cell receptors (TCRs), initiating tailored adaptive immune responses crucial for the control of infections, response to neoplastic cells, and the regulation of immune tolerance[1][3]. There are two main branches of the pathway: MHC class I (presenting intracellular antigens to cytotoxic T cells) and MHC class II (presenting extracellular antigens to helper T cells); both are essential for the immune system’s ability to distinguish self from non-self and to mount an appropriate defense against pathogens and malignant cells[2][3][4]. Disruptions, defects, or dysregulation in this pathway are implicated in a variety of disease contexts, including infections, cancers, and autoimmune disorders[1][3][4].\n\nNotes on "is_target" and "is_incorrect":\n- **This is not a single molecular target** (such as a receptor or enzyme), but a complex cellular pathway involving multiple proteins (MHC molecules, proteasomes, transporters, co-receptors, etc.) and cell types. Therefore, **it is not considered a "therapeutic target"** in the molecular sense, though many drugs or biologics may modulate components of this pathway or the activity of APCs[1][2][4].\n- The entry is somewhat incorrect as a target: "Antigen presentation pathway via APCs" refers to a process or pathway, not a molecule, receptor, or specific druggable target. Individual proteins within this pathway (such as MHC class I or II molecules) can be considered molecular targets[1][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Antigen presentation pathway via antigen-presenting cell.